A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer

Cancer Research

Volumn 62, Issue 12, 2002, Pages 3408-3416

  Dowlati, Afshin ^a,b   Robertson, Kelly ^b   Cooney, Matthew ^a   Petros, William P ^c   Stratford, Michael ^d   Jesberger, John ^b   Rafie, Niusha ^b   Overmoyer, Beth ^a,b   Makkar, Vinit ^a,b   Stambler, Bruce ^a   Taylor, Anne ^e   Waas, John ^a   Lewin, Jonathan S ^b   McCrae, Keith R ^a,b   Remick, Scot C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER PAIN; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEPHOSPHORYLATION; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEMALE; FLUSHING; HEADACHE; HOT FLUSH; HUMAN; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; STOMATITIS; THYROID CANCER; TUMOR BLOOD FLOW;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES;

EID: 0037096814     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Isolation and structure of combretastatin
2. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug
3. Antineoplastic agents 291. Isolation and synthesis of combretastatins A4, A-5, and A-6(1a)
4. Isolation and structure of the strong cell growth and tubulin inhibitor combret-astatin A-4
5. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs
6. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents
7. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
8. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor
9. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub)
10. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours
11. Differential cytotoxicity of combretastatins A-1 and A-4 in two daunorubicin-resistant P388 cell lines
12. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
13. 3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site
14. The interaction with tubulin of a series of stilbenes based on combretastatin A-04
15. Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin
16. Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid
17. Flavone acetic acid-preclinical and clinical activity
18. Tumour necrosis factor-α plasma levels after flavone acetic acid administration in man and mouse
19. Vascular collapse after flavone acetic acid: A possible mechanism of its antitumour action
20. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
21. Vinca alkaloids: Anti-vascular effects in a murine tumour
22. Reduction of tumour blood flow by flavone acetic acid: A possible component to therapy
23. In vivo targets of recombinant human tumour necrosis factor-α blood flow, oxygen consumption and growth of isotransplanted rat tumours
24. Blood flow failure as a major determinant in the anti-tumour action of flavone acetic acid
25. Colchicine in the experimental chemotherapy of cancer
26. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
27. Combretastatin A-4 phosphate as tumor vascular targeting agent: Early effects in tumors and normal tissues
28. Induction of apoptosis in proliferating human endothelial cells by tumor specific antiangiogenesis agent combretastatin A-4
29. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model
30. Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x 5 schedule every 21 days
31. Phase I study of weekly intravenous combretastatin A4 phosphate (CA4P): Pharmacokinetics and toxicity
32. Toxicity and response criteria of the Eastern Cooperative Oncology Group
33. Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography
34. Key factors in the acquisition of contrast kinetic data for oncology
35. Estimating kinetic parameters from dynamic contrast-enhanced TI-weighted MRI of a diffusible tracer: Standardized quantities and symbols
36. Angiogenic attack as a therapeutic strategy for cancer
37. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
38. Vascular targeting as a strategy for cancer therapy
39. Targeting tumour vasculature: The development of combretastatin A4
40. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
41. A new concept for macro-molecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS
42. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
43. Blood vessel maturation: Vascular development comes of age
44. Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man, demonstrated by MRI
45. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
46. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
47. + channel blocker isolated from the 'hiccup nut' toxin
48. Irinotecan therapy in adults with recurrent or progressive malignant glioma
49. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer
50. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: Cancer and Leukemia Group B study
51. Paclitaxel (Taxol)
52. The taxanes: An update
53. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene family
54. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine induced endothelial protein that binds to lymphocytes
55. Selectins
56. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura
57. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities
58. Phase I study of the antineovascularization drug CM101
59. Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis
60. A phase I pharmacokinetic and pharmacodynamic study of SU5416 and doxorubicin (ADR) in inflammatory breast cancer
61. Dynamic contrast enhanced imaging assessment of the effects of antiangiogenic agent SU5416 in inflammatory breast cancer: Preliminary results